![The F-35’s future: The power and cooling competition that could change everything [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/09/240924_F35_moon_USAF-scaled-e1727200160419.jpg?#)
U.S. FDA Grants Approval for Jivi (Antihemophilic Factor (Recombinant), PEGylated-aucl) in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A
WHIPPANY, N.J.--(BUSINESS WIRE) May 19, 2025 --Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII concentrate, for use in pediatric patients 7 years of age...
WHIPPANY, N.J.--(BUSINESS WIRE) May 19, 2025 --Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII concentrate, for use in pediatric patients 7 years of age...
